Abstract Details

Title Levels and Suppressive Effect of Vitamin D on Cytokine Production in Japanese Patients with Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P02 - (-)

Poster/Presentation
Number 106

Objective

Background BACKGROUND: Mapping MS distribution reveals a high prevalence of the disease in high-latitude areas, suggesting a positive relationship between vitamin D and MS.

Design/Methods DESIGN/METHODS: The levels of 25(OH)D, 1,25(OH)2D, and vitamin D-binding protein (VDBP) in serum were measured in 29 patients with relapsing-remitting (RR) and secondary-progressive (SP) MS and in 34 healthy controls. Peripheral blood mononuclear cells (PBMCs) from 19 RRMS patients and 16 SPMS patients and age/sex-matched controls were cultured with phytohemagglutinin (PHA) or lipopolysaccharide (LPS), 1,25(OH)2D was added, and TNF and IL-10 cytokines were measured.

Results RESULTS: The serum levels of 25(OH)D in SPMS patients were significantly decreased compared with those of controls and RRMS patients (7.9 ± 7.2, 24.2 ± 14.2, and 22.5 ± 13.2, respectively). VDBP levels in RRMS and SPMS patients were also decreased compared with controls (419.4 ± 76.2, 416.7 ± 65.9, 527.6 ± 149.4, respectively). Vitamin D decreased TNF and IL-10 production in cultured PBMCs of MS patients and controls. In LPS-stimulated samples, the suppression rate of IL-10 production by vitamin D (IL-10 production in PBMC with or without vitamin D) in RRMS patients was significantly decreased compared with that of controls (0.472 ± 0.118 and 0.618 ± 0.216, respectively, p < 0.05). In PHA-stimulated samples, TNF production due to vitamin D in SPMS patients was significantly higher than that of controls (114.5 ± 81.8 and 66.2 ± 32.1, respectively, p < 0.05).

Conclusions CONCLUSIONS: 25(OH)D levels were lower in SPMS patients. Therefore, vitamin D supplementation is a potential treatment for MS in Japanese as well as Western populations. Vitamin D decreases production of IL-10 and TNF. However, in Japanese MS patients, the suppressive effect on TNF production by vitamin D might be weaker compared with controls.

Authors/Disclosures
Masaaki Niino, MD (Hokkaido Medical Center) PRESENTER	No disclosure on file
	No disclosure on file
Yusei Miyazaki, MD, PhD (Hokkaido Medical Center)	No disclosure on file
Naoya Minami, MD	No disclosure on file
	No disclosure on file
Ajit P. Mishra, MD (Institute of Medical science & SUM Hospital)	No disclosure on file
	No disclosure on file
	No disclosure on file
Maria Trojano (Policlinico - Bari)	Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi_Genzyme. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen.
Seiji Kikuchi, MD (Hokkaido Medical Center)	No disclosure on file

��ɫ��

��ɫ��